Related Experiment Video
Updated: Feb 23, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
The Long and Winding Road Toward Personalized Glycemic Control in the Critically Ill
11 Stamford Hospital, Department of Medicine, Columbia University College of Physicians and Surgeons, Stamford, CT, USA.
Journal of Diabetes Science and Technology
|September 7, 2017
Summary
Intensive insulin therapy in the ICU shows mixed results for critically ill patients. Personalized blood glucose targets, based on preadmission glycemia, may improve outcomes for patients with hyperglycemia.
Area of Science:
- Critical Care Medicine
- Endocrinology
- Metabolic Disorders
Background:
- Hyperglycemia is prevalent in critically ill patients.
- Intensive insulin therapy (IIT) for normal ICU glycemia yields inconsistent outcomes.
- Diabetes status influences glucose-mortality relationships in ICU settings.
Purpose of the Study:
- To investigate the impact of preadmission glycemia on mortality risk in critically ill patients.
- To explore personalized blood glucose targets in the ICU.
Main Methods:
- Analysis of existing literature on hyperglycemia and intensive insulin therapy in ICUs.
- Examination of the relationship between glucose metrics, diabetes status, and mortality.
- Assessment of preadmission glycemia (HbA1c) as a confounding factor.
Main Results:
- Diabetes is not an independent predictor of mortality in critically ill patients.
- Glucose-mortality associations differ between diabetic and non-diabetic ICU patients.
- Preadmission glycemic control (HbA1c) significantly impacts the relationship between ICU glycemia and outcomes.
Conclusions:
- Preadmission glycemic control is a critical factor in determining outcomes for critically ill patients.
- ICU blood glucose targets should be personalized, considering preadmission glycemic status.
- Future strategies may involve tailoring glycemic management based on individual patient profiles.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:14SBAR II: Application of SBAR
6.2K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.2K
01:16Insulin: Dosing Regimen and Adverse Effects
903
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
903
01:22Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
937
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
937